Please login to the form below
David Noble to leave Edelman
David Noble, managing director of Edelman's BioScience division has been made redundant as part of a management restructure
David Noble, managing director of Edelman's BioScience division has been made redundant as part of a management restructure.
Noble has been heading the agency's specialist medical communications business unit for more than three years. He is to leave this month following a three-week consultation process.
Steve Spurr who leads Edleman's ethical healthcare division will take over Noble's responsibilities.
Robert Phillips, Edelman UK CEO told PR Week: "The BioScience and Rx divisions will remain separate, but will be headed by Steve. We are reorganising internally to have more fluent interaction between the teams."
The BioScience division specialises in advisory board management, clinical trial recruitment/retention, market access support, publication planning, meetings and symposia.
Share
Related Hub content
Featured jobs
- Publications Director, Medical Communications agency, Home Based...
-
Competitive Salary
- Strategic Associate Director Healthcare PR, London
-
Substantiel package
- Publications Director, Medical Communications agency, Oxford
-
Competitive Salary
- Client Partner, Healthcare Brand Communications, London
-
Highly competitive package
- Publications Director, Medical Communications agency, Cambridge
-
Competitive Salary
- Account Director, Healthcare Communications
-
Salary TBC
Subscribe to our email news alerts
- Communique Awards 2019: Photo Gallery - Communiqué Awards
- AbbVie’s Skyrizi gets rapid ‘yes’ from NICE
- Amgen and Novartis abandon Alzheimer’s drug after worsening symptoms
- AbbVie’s Skyrizi gets rapid ‘yes’ from NICE
- Moving annual total (MAT)
- Amgen and Novartis abandon Alzheimer’s drug after worsening symptoms
- We are Gold! Porterhouse Medical Group is recognised as an ‘Investor in People’ at the Gold level
- Illumina sets up first ex-US accelerator site in Cambridge
- Kisqali combination follows Verzenio onto Cancer Drugs Fund
- Genentech taps into Sosei Heptares GPCR expertise with $1bn alliance
- ACPs to lead gene therapies in haemophilia market growth
- FDA starts speedy review of Novartis’ sickle cell antibody
PMHub
Bedrock Healthcare Communications
Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...
Latest intelligence
- Precision paediatrics: Treating patients with CAR-T
- Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
- What does it mean to be an agile organisation
- We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
- Battling breast cancer with precision medicine (Part 2)
- Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...
Quick links
Infographics
